Regeneron Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary

Strategic Growth and Platform Validation

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

• Performance was driven by record quarterly net sales for Dupixent, EYLEA HD, and Libtayo, marking the third consecutive quarter of double-digit growth on both top and bottom lines.

• Management attributes EYLEA HD's momentum to its status as nearly two-thirds of the U.S. retinal franchise, with physician demand growing 20% sequentially due to extended dosing intervals and label enhancements.

• The company's 'disease agnostic' R&D strategy leverages core technologies like VelocImmune and siRNA to maintain approximately 50 clinical programs across diverse therapeutic areas rather than being confined to specific specialties.

• The expanded Sanofi alliance for next-generation long-acting antibodies is designed to preserve Dupixent-like efficacy while enabling dosing intervals of every 3 to 6 months, leveraging existing market access leadership.

• Commercial execution is supported by an infrastructure that already calls on a wide range of specialists, allowing new pipeline assets to launch into established channels with deep existing relationships.

• Libtayo's 81% U.S. sales growth was fueled by its position as the leading immunotherapy in non-melanoma skin cancers and the second most prescribed in non-small cell lung cancer.

Pipeline Milestones and Investment Outlook

• 2027 R&D expense is projected to increase by a mid-teens percentage to support the advancement of approximately 15 Phase 3 trials across myeloma, anticoagulation, and obesity.

• Management expects an FDA decision for cemdisiran in generalized myasthenia gravis in November, which would represent the first siRNA therapy for the condition with quarterly subcutaneous dosing.

• The company plans to initiate potentially registrational studies for its POTS antibody program and CIDEB siRNA for NASH in 2027, pending regulatory feedback on initial clinical data.

• Guidance for the fourth quarter assumes continued EYLEA HD momentum with sequential growth of approximately 10%, partially offset by ongoing pricing pressure in the retinal market.

• Regarding the 2027 effective tax rate, the company expects approximately 100 to 200 basis points of upward pressure relative to 2026, which is consistent with prior long-term tax rate commentary.

Financial Adjustments and Strategic Shifts

• Third quarter Ilaris royalty revenue included an approximately $60 million cumulative catch-up adjustment that management confirmed will not recur in the fourth quarter.

• The company completed the repayment of the Sanofi development balance in the second quarter, allowing Regeneron to record its full share of collaboration profits for the first time this period.

• Management signaled a shift in business development strategy, moving from being a historical net out-licenser to actively evaluating external innovation from early-stage platforms to commercial-stage products.

• A new BARDA agreement for Inmazep will supply doses to the U.S. government starting in late 2027, resulting in no anticipated revenue from this program in the fourth quarter of 2026.